Record Q4 performance was primarily driven by a 14.1% increase in advanced imaging volumes, which now represent over 60% of total revenue and serve as the primary margin catalyst.

Management attributes volume growth to a structural shift of procedural care away from expensive hospital settings toward RadNet's lower-cost ambulatory freestanding centers.

The acquisition of Paris-based Gleamer establishes RadNet as the world's largest radiology clinical AI provider, adding 700 customer contracts across 44 countries to the DeepHealth portfolio.

Operational efficiency is being targeted through 'agentic AI' and automated draft reporting to address acute global shortages of radiologists and technologists.

Strategic positioning focused on 'routine imaging' (X-ray, ultrasound, mammography) aims to capture high-volume workflows that account for approximately 25% of RadNet's total imaging volume.

The company maintained a disciplined capital structure, ending 2025 with a net debt to adjusted EBITDA leverage ratio of approximately 1.0 despite significant acquisition activity.

2026 guidance anticipates Imaging Center revenue growth of 17% to 19%, driven by same-center performance, de novo openings, and recent acquisitions in Florida and Indiana.

Digital Health revenue is projected to grow 45% to 55%, with Annual Recurring Revenue (ARR) expected to approach $140 million by the end of 2026.

Management expects to achieve at least four new FDA clearances in 2026 across mammography, lung, prostate, thyroid, and brain applications.

The financial framework assumes approximately 4% growth in same-center labor costs and accounts for early Q1 headwinds from severe winter weather in the Mid-Atlantic and Northeast.

Free cash flow is projected to grow 29% to 41% as EBITDA expansion is expected to outpace capital expenditure and interest expense increases.

The Gleamer acquisition includes an EBITDA loss of approximately $5 million embedded in 2026 guidance, with a target to reach profitability by mid-2027.

Labor market constraints remain a primary headwind, necessitating continued investment in AI-powered workflow automation to sustain capacity.

The company introduced Annual Recurring Revenue (ARR) as a new key metric to provide transparency into the transition toward a subscription-based Digital Health model.

Pro forma leverage is expected to rise to between 1.6x and 1.8x following the completion of the Gleamer, Indiana, and Florida transactions.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Management clarified that AI is viewed as a productivity and accuracy tool rather than a replacement for human labor, specifically citing a 20% to 22% increase in early breast cancer detection.

The strategy focuses on making an insufficient workforce more capable of handling unabated demand driven by technological advances in imaging equipment.

The bridge to $140 million includes the $75 million 2025 base, $30 million from Gleamer, $7 million from iCAD annualization, and $27 million in organic SaaS growth.

Growth is expected across three domains: Clinical AI, Enterprise Imaging (PACS), and Enterprise Operations (RIS).

RadNet expects productivity impacts as early as Q3 2026 by deploying Gleamer's tools to automate findings and triage in high-volume X-ray workflows.

The long-term goal is 'automated reporting' where AI creates clinical reports without human intervention, a feature already in early deployment in Europe.

Inbound interest from hospital systems has increased significantly due to acute radiologist staffing shortages.

Management expects to announce new or expanded health system relationships in 2026 as hospitals seek outpatient imaging strategies and better informatics.

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.